SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]
SEC Accession No. 0001558370-22-013514
Filing Date
2022-08-12
Accepted
2022-08-12 16:40:52
Documents
84
Period of Report
2021-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q/A nrxp-20210630x10qa.htm   iXBRL 10-Q/A 1996392
2 EX-31.1 nrxp-20210630xex31d1.htm EX-31.1 15358
3 EX-31.2 nrxp-20210630xex31d2.htm EX-31.2 15447
4 EX-32.1 nrxp-20210630xex32d1.htm EX-32.1 7089
5 EX-32.2 nrxp-20210630xex32d2.htm EX-32.2 6411
  Complete submission text file 0001558370-22-013514.txt   9587445

Data Files

Seq Description Document Type Size
6 EX-101.SCH nrxp-20210630.xsd EX-101.SCH 82878
7 EX-101.CAL nrxp-20210630_cal.xml EX-101.CAL 40055
8 EX-101.DEF nrxp-20210630_def.xml EX-101.DEF 317959
9 EX-101.LAB nrxp-20210630_lab.xml EX-101.LAB 496092
10 EX-101.PRE nrxp-20210630_pre.xml EX-101.PRE 497074
78 EXTRACTED XBRL INSTANCE DOCUMENT nrxp-20210630x10qa_htm.xml XML 1856943
Mailing Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801
Business Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

IRS No.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q/A | Act: 34 | File No.: 001-38302 | Film No.: 221160766
SIC: 2834 Pharmaceutical Preparations